Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada (vol 25, pg 32, 2018)

被引：0
|
作者：
Chua, A.
Perrin, A.
Ricci, J. F.
Neary, M. P.
Thabane, M.
机构：
来源：
CURRENT ONCOLOGY | 2018年 / 25卷 / 04期
关键词：
D O I：
10.3747/co.25.4233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E354 / E355
页数：2
相关论文
共 50 条
  • [31] What is the potential cost-effectiveness of enforcing a prohibition on the sale of tobacco to minors? (vol 32, pg 168, 2001)
    DiFranza, JR
    Peck, RM
    Radecki, TE
    Savageau, JA
    PREVENTIVE MEDICINE, 2001, 33 (03) : 227 - 227
  • [32] Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey
    Balcik, Pinar Yalcin
    Sahin, Bayram
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (01) : 152 - 158
  • [33] COST-EFFECTIVENESS OF PROSTATE-CANCER SCREENING AND TREATMENT (VOL 119, PG 1055, 1993)
    GARNICK, MB
    ANNALS OF INTERNAL MEDICINE, 1994, 120 (08) : 698 - 698
  • [34] The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study (vol 36, pg 1263, 2018)
    Leal, Jose
    Manetti, Stefania
    Buchanan, James
    PHARMACOECONOMICS, 2019, 37 (06) : 867 - 867
  • [35] Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
    Yao, James C.
    Oh, Do-Youn
    Qian, Jiaming
    Park, Young Suk
    Herbst, Fabian
    Ridolfi, Antonia
    Izquierdo, Miguel
    Ito, Tetsuhide
    Jia, Liqun
    Komoto, Izumi
    Sriuranpong, Virote
    Shimada, Yasuhiro
    ONCOTARGETS AND THERAPY, 2019, 12 : 1717 - 1728
  • [36] Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
    Ondhia, Umang
    Conter, H. J.
    Owen, Scott
    Zhou, Anna
    Nam, Julian
    Singh, Sumeet
    Abdulla, Ahmed
    Chu, Paula
    Felizzi, Federico
    Paracha, Noman
    Sanghag, Randeep
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) : 625 - 637
  • [37] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
  • [38] A cost-effectiveness analysis of propofol versus midazolam for procedural sedation in the emergency department (vol 15, pg 32, 2008)
    Hohl, Corinne Michele
    Nosyk, Bohdan
    Sadatsafavi, Mohsen
    Anis, Aslam Hayat
    ACADEMIC EMERGENCY MEDICINE, 2008, 15 (03) : 304 - 304
  • [39] Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia (vol 40, pg 133, 2012)
    Floyd, Katherine
    Hutubessy, Raymond
    Kliiman, Kai
    Centis, Rosella
    Khurieva, Nina
    Jakubowiak, Wieslaw
    Danilovits, Manfred
    Peremitin, Genadi
    Keshavjee, Salmaan
    Migliori, Giovanni Battista
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (03) : 800 - 800
  • [40] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    VALUE IN HEALTH, 2019, 22 : S165 - S166
12345